Back to top

biotechnology: Archive

Ahan Chakraborty

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?

Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.

SNYPositive Net Change RHHBYNegative Net Change RLAYPositive Net Change RXRXPositive Net Change

Zacks Equity Research

REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

REGNNegative Net Change VRTXNegative Net Change MRNAPositive Net Change HRMYPositive Net Change

Zacks Equity Research

New Strong Buy Stocks for July 25th

PHIN, MBWM, THC, RVLV and PHAR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2025.

THCPositive Net Change MBWMNegative Net Change RVLVPositive Net Change PHARPositive Net Change PHINPositive Net Change

Zacks Equity Research

Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

RDYNegative Net Change MRKPositive Net Change AMGNNegative Net Change ALVOPositive Net Change

Ekta Bagri

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

BMYNegative Net Change PFENegative Net Change MRKPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well

RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.

REGNNegative Net Change RHHBYNegative Net Change PRTANegative Net Change

Ekta Bagri

Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?

Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.

BMYNegative Net Change JNJNegative Net Change KROSPositive Net Change

Zacks Equity Research

Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?

EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.

ALKSNegative Net Change INCYNegative Net Change EXELPositive Net Change AKROPositive Net Change

Ahan Chakraborty

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

SDGRNegative Net Change RLAYPositive Net Change RXRXPositive Net Change

Zacks Equity Research

AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures

AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.

AZNNegative Net Change NVSPositive Net Change JNJNegative Net Change LLYPositive Net Change

Zacks Equity Research

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.

RHHBYNegative Net Change BAYRYPositive Net Change SRPTNegative Net Change VRNAPositive Net Change

Zacks Equity Research

New Strong Sell Stocks for July 22nd

BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.

DDDNegative Net Change ANNXNegative Net Change BLTEPositive Net Change